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The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the
available evidence for the ten most important areas of controversy in advanced prostate cancer (APC) management. The
successful registration of several drugs for castration-resistant prostate cancer and the recent studies of chemo-hormonal
therapy in men with castration-naïve prostate cancer have led to considerable uncertainty as to the best treatment
choices, sequence of treatment options and appropriate patient selection. Management recommendations based on
expert opinion, and not based on a critical review of the available evidence, are presented. The various recommendations
carried differing degrees of support, as reflected in the wording of the article text and in the detailed voting results
recorded in supplementary Material, available at Annals of Oncology online. Detailed decisions on treatment as always will
involve consideration of disease extent and location, prior treatments, host factors, patient preferences as well as logistical
and economic constraints. Inclusion of men with APC in clinical trials should be encouraged.
Key words: advanced prostate cancer, castration-resistant prostate cancer, therapeutics, consensus, castration-naïve
prostate cancer
introduction
The diagnostic and therapeutic management of men with
advanced prostate cancer (APC) has been transformed in recent
years. Several new treatments for men with castration-resistant
disease have successfully completed phase III trials and have
received regulatory approval. The trials have not only shown a
significant prolongation of overall survival, but they also
reported improved or preserved quality of life (QoL). The latter,
however, was less rigorously assessed and documented.
Importantly, the currently approved survival-prolonging treat-
ments in metastatic castration-resistant prostate cancer (CRPC)
have distinct mechanisms of action. These therapies include
unique classes of agents: taxanes, docetaxel and cabazitaxel, an
immunotherapeutic agent, sipuleucel-T, novel androgen recep-
tor (AR) pathway inhibitors abiraterone acetate (abiraterone)
and enzalutamide as well as a bone targeting alpha-emitting
radionuclide, radium-223 chloride (radium-223) [1–7].
Large-scale, prospective randomised trials testing the optimal
sequencing of these treatments have not yet been reported.
Furthermore, predictive markers to facilitate the selection of
patients for a specific therapy or sequence of therapies remain
an unmet need. The latter is especially relevant given the in-
creasing evidence that some castration-resistant phenotypes
may be more responsive to hormonal strategies, others to cyto-
toxics and others to biologic approaches. Effective combination
therapies may improve outcomes and are under investigation. In
addition, trials examining newer agents in the castration-naïve
setting are now beginning to emerge, potentially supporting the
upfront use of agents such as docetaxel. While addressing one
aspect of the sequencing debate, such upfront use clearly then
raises a whole raft of new questions about management on
development of CRPC.
Novel imaging methods for evaluation of patient selection
and response claiming increased sensitivity and specificity have
not been adequately tested in prospective clinical trials.
In the absence of evidence, the selection of treatment is based
on clinical judgement that includes the experience of the treat-
ing physician with the available agents, the status of the disease,
when the patient is presenting for treatment, and potential co-
morbid conditions that might preclude a particular treatment.
All treatments can have side-effects, and all of the new treat-
ments are expensive. Of note, global access to the above-
mentioned CRPC therapeutics varies across the globe, and the
financial burden to an individual patient, but also to the com-
munity, must be factored.
Zoledronic acid and denosumab are approved to reduce the
risk of skeletal-related events (SREs) based on the results of
phase III trials in men with metastatic CRPC [8–10]. Most were
approved before the availability of therapies beyond taxanes.
The optimal use of these osteoclast-targeted therapies (including
sequencing, initiation, frequency and duration of treatment) has
not been determined. Moreover, their roles, and in particular
their efficacy, in the era of newly approved anticancer-treatment
options for men with CRPC [many of which also reduce the risk
of SREs or symptomatic skeletal-related events (SSEs)] have not
been determined. Studies to address these critical knowledge
gaps need to be undertaken.
Physicians may rely on national and international guidelines
to base management decisions outside of clinical trials. The level
of evidence on which a specific guideline is based varies consider-
ably. Nonetheless, there still remain several topics regarding man-
agement decisions where there is either a paucity of level one
evidence or conflicting evidence of results. To address this, an
international expert consensus, the St Gallen Advanced Prostate
Cancer Consensus Conference (APCCC), was organised with the
objective of providing the recommendations of experts to comple-
ment evidence-based guidelines and to better frame the discussion
between men with prostate cancer and physicians when faced with
management decisions.
Importantly, several of these recommendations were derived
from clinical trial data that have been obtained from trials with
specific entry criteria. These criteria will differ from trial to trial.
Hence, not all recommendations can be generalised and applied
uncritically to every patient, rather they should be tailored to an
individual and shared decision making is still required.
methods
The panel included 41 prostate cancer experts from 17 countries, covering
different specialties involved in research and treatment of men with APC
(Table 1).
First, the panel members agreed upon the 10 most important areas of
controversy relating to the management of men with APC, and these are
listed below:
(i) Management of men with castration-naïve metastatic prostate cancer
(ii) Management of men with oligometastatic castration-naïve prostate
cancer
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(iii) Definition of castration resistance
(iv) Management of men with non-metastatic (M0) CRPC
(v) Value of endocrine manipulations without proven survival benefit in
men with metastatic CRPC
(vi) Treatment choice and sequencing for men with metastatic CRPC
(vii) Staging and monitoring of treatment
(viii) Use of osteoclast-targeted agents for reducing risk of SREs and SSEs
in men with CRPC
(ix) Value and use of predictive markers
(x) Multidisciplinary care of men with prostate cancer
In a modified Delphi process (Figure 1), questions based on the above 10
sections (Figure 2) were created and in the first round sent to all panel
members for input. Questions and options for answers were later revised
and sent a second time to all panel members, including all inputs received
shown in an anonymised fashion, so all the panellists could see every
comment from their colleagues [11]. The comments from the second round
were included in the third version which was then circulated. After the third
round, only important changes were accepted for the fourth and final version
of the questions. This process was analogous to the one used for the St Gallen
International Expert Consensus on the Primary Therapy of Early Breast
Cancer [12]. The conference included presentations and debates from partici-
pants (primarily from panellists) who reviewed evidence relevant to the above
questions. On the last day of the conference, all questions were presented with
options for answers in a multiple-choice format. The questions were voted on
publicly but anonymously. In some cases, discussions and re-voting occurred.
For all questions, if not stated otherwise, it was assumed that any drug
recommended must have been approved and was readily available, no treat-
ment contraindications existed and no clinical trial was available. In addition
recommendations applied only to non-frail patients [defined as Eastern
Cooperative Oncology Group (ECOG) performance status 0–2] and for
patients with adenocarcinoma of the prostate (if not stated otherwise).
Importantly, in an effort to address questions from an evidenced-based and
Table 1. Panel members by country and specialty
Name Country Specialty
Akaza, Hideyuki Japan Urology
Attard, Gerhardt UK Medical Oncology
Beer, Tomasz M. USA Medical Oncology
Beltran, Himisha USA Medical Oncology
Chinnaiyan, Arul M. USA Pathology/Basic research
Daugaard, Gedske Denmark Medical Oncology
Davis, Ian Australia Medical Oncology and
Palliative Medicine
De Bono, Johann UK Medical Oncology
De Santis, Maria Austria Medical Oncology
Drake, Charles G. USA Medical Oncology
Eeles, Rosalind Anne UK Oncogenetics and Clinical/
Radiation Oncology
Efstathiou, Eleni Greece/USA Medical Oncology
Fanti, Stefano Italy Nuclear Medicine
Fizazi, Karim France Medical Oncology
Gillessen, Silke Switzerland Medical Oncology
Gleave, Martin E. Canada Urology
Halabi, Susan USA Statistics/Epidemiology
Heidenreich, Axel Germany Urology
Hussain, Maha H. A. USA Medical Oncology
James, Nicholas D. UK Clinical/Radiation Oncology
Lecouvet, Frédéric Belgium Radiology
Logothetis, Christopher J. USA Medical Oncology
Nelson, Peter USA Medical Oncology
Nilsson, Sten Sweden Medical Oncology
Oh, William K. USA Medical Oncology
Olmos, David Spain Medical Oncology
Padhani, Anwar UK Radiology
Parker, Chris UK Clinical/Radiation Oncology
Rubin, Mark A. USA Pathology/Basic research
Sartor, Oliver A. USA Medical Oncology
Schalken,Jack A. Holland Basic research
Scher, Howard I. USA Medical Oncology
Sella, Avishay Israel Medical Oncology
Shore, Neal USA Urology
Small, Eric USA Medical Oncology
Smith, Matthew R. USA Medical Oncology
Sternberg, Cora N. Italy Medical Oncology
Suzuki, Hiroyoshi Japan Urology
Sweeney, Christopher USA Medical Oncology
Tannock, Ian Canada Medical Oncology
Tombal, Bertrand Belgium Urology
Panel selected (41members: urology, medical
oncology, clinical oncology, radiology, nuclear
medicine, pathology, statistics, genetics) 
Draft consensus questions
First round (August 2014): Questions sent to
ALL panel members. 
Second round (November 2014): Revised
questions and all comments sent to ALL panel
members 
Consensus questions are debated and voted
on during the conference 14. March 2015
Definition of most important areas of controversy in
advanced prostate cancer management
Manuscript v2, v3, vX circulated until
agreement achieved
Manuscript v1 circulated to all panel members
April 2015
Final manuscript submitted for peer review
publication
Publication and endorsement through
national and international organisations
Third round (January 2015): Only important
and urgent comments. Confirmation from ALL
panel members required
Figure 1. How the Consensus Process works (modified Delphi process).
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clinical utility perspective, panellists were specifically instructed not to
factor in cost, reimbursement and access as factors in their deliberations,
although clearly these are critical factors in decision making for the individ-
ual patient.
It was recommended that if a panellist lacked experience or was non-
expert for a specific question, the option ‘unqualified to answer’ (short form
‘unqualified’) should be chosen and if a panellist felt unable to vote for a best
choice for any reason or had prohibitory conflicts of interest (COI), the
option ‘abstain’ should be chosen. The conference also included an explicit
approach to management of COI (supplementary Appendix S1, available at
Annals of Oncology online).
For the purposes of this article, the term ‘recommend’ is used to reflect
the fact that the panellists considered the option as the preferred one, also in
the absence of hard clinical trial data. In contrast, the use of the phrase
‘discuss the option’ was used when panellists felt that the option was a con-
sideration, but not necessarily the preferred one.
Detailed voting records for each of the questions brought to the panel are
provided in the supplementary Appendix S2, available at Annals of Oncology
online. In tabulating the results, the denominator was based on the number
of panel members who voted, excluding those that were ‘unqualified to
answer’ but including those who chose to ‘abstain’.
If 75% of the panellists chose the same option, this was defined as con-
sensus. All panellists have contributed to the editing and approved this final
consensus document.
Importantly, this process was also able to emphasize areas of non-consen-
sus where additional data acquisition might be warranted.
management of men with castration-naïve
metastatic prostate cancer
The panel members felt that ‘castration-naïve’ is the more appropriate term
instead of ‘hormone-sensitive’ or ‘castration sensitive’, as the sensitivity of
the cancer to castration is not known before commencement of Androgen
deprivation therapy (ADT).
intermittent and combined ADT. ADT by means of orchiectomy,
GnRH agonists or antagonists is the standard systemic treatment of
metastatic prostate cancer [13–18].
The data supporting equivalence of GnRH analogues and orchiectomy
were primarily established by studies using a testosterone suppression end
point rather than appropriately sized and powered clinical trials with an end
point of clinical efficacy. The majority of patients in economically well-devel-
oped countries today are treated with medical castration whereas, in develop-
ing countries, surgical castration is a more commonly used option for ADT
[19]. Although the majority of the patients experience a profound prostate-
specific antigen (PSA) decline with ADT, the median failure-free survival is1
year, yet with a wide range. (11.2 months; interquartile range: 5.1–28.8) [20].
The concept of using ADT intermittently instead of continuously was
developed as a consequence of several different hypotheses. These included
the theory, based on experimental models [21–23], that intermittent use of
ADT might be associated with a delay in development of castration resistance
and the expectation that it would lead to less toxicity resulting in improve-
ments in QoL and reduction in costs of treatment during the off phase.
Intermittent ADT (iADT) versus continuous ADT in men with metastatic
prostate cancer has been evaluated in several trials, but only two trials have
included solely metastatic patients and used the end point of overall survival.
One of these trials was small (n = 173) whereas the SWOG 9346 trial rando-
mised more than 1500 patients with initial PSA decline on ADT [24, 25].
The results of the latter trial failed to provide clear evidence for non-inferior-
ity of iADT compared with continuous ADT [hazard ratio (HR) for death
1.1, 95% confidence interval (CI) 0.99–1.23]. The median overall survival
(OS) was longer in the continuous ADT arm (5.8 versus 5.1 years) compared
with the iADT arm. The findings serve to reject the theory of delay in castra-
tion resistance via iADT.
A recent systematic review by Niraula et al. has summarised the results of
9 studies with 5508 patients [24]. This review included men with various
stages of disease, including those starting treatment of rising PSA after local
treatment and trials with different end points. The authors concluded that
there is evidence to recommend use of iADT (combined HR for OS = 1.02).
Situation
M0 M0 M0
Castration-resistant (CRPC)Castration-Naïve
M1 M1first-line
M1
second-line
M1
third-line
Management of men with
castration-naïve metastatic
prostate cancer
Management of men with
oligometastatic
castration-naïve prostate
cancer
Definition of castration resistance
ADT
ADT
Value of endocrine manipulations without proven
survival benefit in men with metastatic CRPC
Treatment choice and sequencing for men with
metastatic CRPC
Staging and monitoring of treatment
Use of osteoclast-targeted agents for reducing risk of
SREs and SSEs in men with CRPC
ADT: Androgen deprivation therapy
M0: No evidence of metastases on imaging
M1: Metastases documented on imaging
Value and use of predictive markers
Multidisciplinary care of men with prostate cancer
Situation
M1
Management of men with non-metastatic (M0) CRPC
Figure 2. Conceptual framework: advanced prostate cancer.
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However, meta-analysis does not replace data from large prospective trials.
Therefore, the value of iADT in men with metastatic castration-naïve pros-
tate cancer is still controversial since the only study powered and designed to
assess non-inferiority, the SWOG 9346 trial, failed to show non-inferiority
of iADT compared with continuous ADT.
In patients with metastatic prostate cancer achieving an adequate PSA
decline (confirmed PSA fall below 4 ng/ml after 6 months of ADT), 71% of
the panellists recommended intermittent instead of continuous ADT only for
a minority of selected patients.
In a clear consensus, 94% of the panellists would discuss the option of inter-
mittent ADT in metastatic patients, 54% in the majority of patients and 40%
in a minority of selected patients who achieved an adequate PSA decline.
For physicians, the interpretation of non-inferiority trials in general and
non-positive non-inferiority trials in particular may be challenging especially
when applied to the clinical setting and patient management.
Due to the fact that residual androgen production by the adrenals may
stimulate prostate cancer growth [25, 26] another attempt to improve the
results of ADT treatment alone is combined (or maximal) androgen block-
ade (CAB), using a permanent combination of ADT and an earlier gener-
ation of AR antagonist such as bicalutamide or flutamide. Several phase III
trials have evaluated the utility of front-line CAB (generally compared with
the late addition of an AR antagonist to gonadal androgen suppression). Of
note, most trials did not use the AR antagonist bicalutamide.
Three separate meta-analyses based on the results of these trials have con-
cluded that there is a 3%–5% overall survival advantage of CAB versus ADT
alone that is statistically significant when less effective steroidal AR antago-
nists such as cyproterone acetate are excluded from the analysis [27–29].
Of note, one Japanese trial was positive, testing CAB with bicalutamide,
raising the possibility that Asian patients may benefit more than other
patients from this treatment [30, 31].
Half of the panel did not recommend CAB whereas 35% recommended it in a
minority of selected patients and 15% recommended it in the majority of patients.
Considerations influencing the use of CAB include ethnicity and added
toxicity. Data about CAB using a combination of GnRH analogues with
newer, more potent AR pathway inhibitors are not yet available.
docetaxel in men with castration-naïve metastatic prostate
cancer. ADT alone versus ADT plus docetaxel in patients with metastatic
castration-naïve prostate cancer has been tested in two randomised phase III
trials, which both reported improved progression-free survival but provided
results which differ in respect to overall survival benefit. The French GETUG-
15 trial (n= 385) reported no OS benefit [32, 33] whereas, in the US ECOG
E3805 (CHAARTED) trial (n = 790), a clinically and statistically significant
improvement in OS was demonstrated [34]. Both trials included a high
proportion of men (>70%) who presented with de novo metastatic prostate
cancer, and this patient population may not be representative of men who
develop metastatic disease at some time after diagnosis of localised cancer.
The different OS results between the trials may be due to sample size, a
lower percentage of patients with higher tumour volume patients in
GETUG-15 (47% versus 65% in CHAARTED), differential use of subse-
quent life-prolonging treatments (including docetaxel) and/or geographic
differences (e.g. prevalence of PSA screening).
Sixty-one percent of the panellists accepted the high-volume definition as
used in CHAARTED [visceral (lung or liver) and/or 4 bone metastases, at
least one beyond pelvis and vertebral column] for use in daily clinical practice,
whereas 11% recommended the high-volume definition developed by SWOG
[visceral (lung or liver) and/or any appendicular skeletal involvement] [35], and
14% recommended the definition of Glass [diffuse bone disease (chest, head and/
or extremities) and/or visceral organ (lung or liver) involvement] [36].
Half of the panel recommended docetaxel with ADT in castration-naïve
M1 patients with high-volume disease in the majority of patients, 39% in a
minority. Eleven percent did not recommend docetaxel with ADT in these
patients at all. In contrast, in patients with low-volume disease, 74% of the
panellists did not recommend routine use of docetaxel with ADT (Figure 3A).
Of note at the time of the consensus meeting (March 2015), the votings
above were based on the published data of GETUG15 and ASCO 2014
meeting presentation of CHAARTED, knowing the STAMPEDE study
would read out in 2015 after the consensus meeting. As such, the consensus
votings do not reflect the results of the M1 arm of the STAMPEDE study.
The subsequent consensus meeting planned for 2017 will make use of the
peer reviewed published data from all three studies and will aim to address
issues such as patient profile, performance status, metastatic load, subse-
quent therapies and other related factors.
An abstract of data of four arms of the STAMPEDE trial (n = 2962 men
with high-risk locally advanced or metastatic prostate cancer) was presented
at ASCO 2015. Median OS was 67 months in the standard of care (ADT)
arm compared with 77 months in the arm in which docetaxel was added to
ADT (HR 0.76, 95% CI 0.63–0.91) [37].
osteoclast-targeted therapy in men with M1 castration-naïve
prostate cancer. A randomised phase III trial (CALGB 90 202; n = 645)
with the bisphosphonate zoledronic acid was conducted in the castration-
naïve metastatic bone setting [38]. Compared with placebo, zoledronic acid
did not improve time to first SRE, the primary study end point, or overall
survival. Denosumab has not been tested for reducing risk of SREs in
castration-naïve prostate cancer.
There was consensus among panellists that patients with castration-naïve pros-
tate cancer and bone metastases should not receive zoledronic acid (81% of the
panel) or denosumab (79% of the panel) for reducing risk of SREs (Figure 4A).
Unfortunately, the approval indications for these drugs oftentimes are not
defined clearly for the castration-resistant setting and, hence, may lead to
their overuse and increase the incidence of their toxicities including osteo-
necrosis of the jaw and (potentially life threatening) hypocalcaemia and/or
hypophosphataemia.
Notably, denosumab and bisphosphonates (at lower dose or schedule
than for reducing risk of SREs) have an established role for the treatment/
prevention of osteoporosis/osteoporotic fractures. The panel did not review
the use of osteoclast-targeted therapy for treatment/prevention of osteopor-
osis and osteoporotic fractures.
oligometastatic castration-naïve prostate cancer
As in other tumour types, there is growing evidence that prostate cancer
patients diagnosed with a limited number of metastases (oligometastatic)
may have a better prognosis compared with those with extensive metastatic
recurrence [39]. A recent meta-analysis of 15 single-arm case series in
patients with oligometastatic disease concluded that local treatment of me-
tastases in this setting may be promising but that the low level of evidence
does not allow its recommendation as standard of care [40].
There was consensus (85% of the panel) that the presence of 3 synchron-
ous metastases (bone and/or lymph nodes) is the most meaningful definition
of oligometastatic prostate cancer.
The panel addressed whether local treatment of both the primary and
all evident metastases was appropriate in patients with oligometastatic
disease. Sixty-two percent of the panel did not recommend using this ap-
proach instead of systemic treatment (ADT) and 38% recommended it only
in a minority of selected patients. When this local therapy was considered
in the context of additional short-term ADT, 62% of the panel recom-
mended this treatment in a minority of selected patients and 27% of the
panel recommended this treatment in the majority of patients.
Similarly, in the case of relapse with oligometastatic disease after radical
local treatment, 58% of the panel did not recommend local treatment of all
metastases instead of systemic treatment (ADT), but 39% of the panel would
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consider it in a minority of selected patients. In the context of additional
short-term ADT, 27% of the panel did not recommend local treatment of all
metastases, 46% of the panel recommended it in a minority of selected patients
and 27% of the panel recommended this treatment in the majority of patients.
The panel recognised that the use of bone scintigraphy and computed
tomography (CT), compared with newer magnetic resonance imaging
(MRI) and positron emission tomography (PET)/CT imaging modalities,
may result in an underestimation of lesion number. This in turn makes
recommendations for a specific therapeutic approach of the oligometastatic
state even more difficult [41–43].
definition of castration resistance
Over time, castration resistance has been defined in multiple ways, and with
the approval of novel agents for the treatment of CRPC it is important to
clarify the definition.
There was clear consensus (94% of the panel) that testosterone levels need
to be measured and a specific value is required to designate a patient castra-
tion-resistant. As a consensus, 82% of the panel recommended a testosterone
level <50 ng/dl (<1.7 nmol/l) as an appropriate cut-off value in daily clinical
practice, which is in line with the US FDA definition.
 
A: Do you recommend docetaxel in addition to ADT in men with
castration-naive “high-volume” disease?
B: Do you recommend docetaxel in addition to ADT in M1 men with
castration-naive “low-volume” disease
Endocrine
manipulation
without proven
survival benefit
84%
ADT 
+/- Docetaxel
ADT M1 castration-naïve
 
C: If you recommend treatment for M0 CRPC outside of clinical trials:
what is your preferred treatment option for men with M0 CRPC
(negative imaging, rising PSA) apart from maintaining ADT?
No treatment option with proven survival benefit
M0 CRPC
Consider clinical trial participation
No
11%
Abstain
13%
Majority
50%Minority
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D: Do you recommend abiraterone or enzalutamide as first-line therapy for
otherwise healthy, asymptomatic or minimally symptomatic men with CRPC?
E: Do you recommend chemotherapy as first-line therapy for
otherwise healthy asymptomatic/minimally symptomatic men with CRPC?
F: Do you recommend Sipuleucel-T as first-line therapy for otherwise
healthy, asymptomatic men with CRPC without visceral metastases?
*Bone metastases and symptomatic, no visceral or bulky lymph node metastases, not fit, unwilling to have no access to chemotherapy or post-chemotherapy
** Low tumour volume, no visceral metastases 
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G: Do you recommend chemotherapy (usually taxane based) as
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Figure 3. (A, B and C) Summary of treatment options for advanced prostate cancer, March 2015.
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Again there was clear consensus (94% of the panel) that a confirmed (by a
second value three or more weeks later) rising PSA on ADT in the presence of
suppressed testosterone is sufficient for the characterisation of a castration-
resistant state in clinical practice.
In case of a rising PSA on ADT, and if testosterone level is not adequately
suppressed, luteinizing hormone (LH) can be measured. In case of non-
suppressed LH, correct administration of the GnRH analogue should be
verified.
If testosterone is not sufficiently suppressed in the presence of suppressed
LH, the panel considered several next management options including bilateral
orchiectomy (22%), change to alternative GnRH agonist (22%), change to
GnRH antagonist (44%) or addition of an AR antagonist (9%).
management of men with non-metastatic (M0)
CRPC
The definition of M0 prostate cancer (rising PSA on ADT and no documen-
ted metastatic disease with radiographic imaging) is dependent upon the
imaging technology chosen. In current clinical practice, the ideal combin-
ation of imaging methods to define the M0 state is unclear, as is when to use
it. M0 is arguably an artificial disease stage designation, as there is a high
likelihood that systemic micro-metastases are missed by commonly used
imaging tools (CT and bone scintigraphy). In the absence of data from posi-
tive prospective clinical trials concerning overall survival, it is unclear what
treatment options should be recommended if no metastases are found radio-
graphically and the PSA continues to rise.
Of note, the randomised trials conducted in this setting with bone-tar-
geted therapies with the objective of delaying the onset of bone metastases
were either negative or not convincingly positive [8, 44, 45]. In the placebo
arm of the trial testing denosumab in this setting, time to first bone
metastasis was 40.8 months in the overall population, and 26 and 18.5
months in the patients with a PSA doubling time (PSA-DT) 10 and 4
months, respectively [46].
There was clear consensus (91% of the panel) that a PSA-based trigger
(level and/or kinetics) should be used for restaging asymptomatic patients
with rising PSA on ADT and no known metastases.
The earlier detection of metastases with newer imaging methods (i.e.
techniques other than CT and planar bone scintigraphy) and consequent
earlier initiation of treatment has not been shown to be associated with a
patient benefit.
There was consensus (77% of the panel) that in daily clinical practice a
negative CT (thorax and abdomen and pelvis) and a negative bone scintig-
raphy are sufficient for diagnosis of M0 disease.
With regards to the total PSA cut-off to initiate imaging, the entire panel
recommended a PSA below 20 as cut-off, almost equally divided between a
PSA of between 2 and 10 (54%) and a PSA between 10 and 20 (46%). The pre-
ferred absolute value is influenced by the prior local therapy (radical prosta-
tectomy versus radiation therapy) and PSA-DT. For PSA-DT as a trigger for
imaging, 74% of the panel recommended a PSA-DT of 6 months, and 9%
recommended a PSA-DT of 3 months.
A risk-adapted strategy, taking PSA level and kinetics as well as patient
preference and characteristics into consideration should be adopted.
Suggestions for when to initiate and repeat imaging in M0 CRPC patients
have been recently published by the Prostate Cancer Radiographic
Assessments for Detection of Advanced Recurrence Group [47].
As a trigger to initiate systemic treatment of M0 CRPC, about half of the
panel (52%) recommended a combination of PSA-DT and absolute PSA value
whereas 30% of the panel did not recommend treatment of patients with M0
CRPC outside of clinical trials at all, irrespective of PSA level and kinetics.
*Bone metastases and symptomatic, no visceral or bulky lymph node metastases, not fit, unwilling to have no access to chemotherapy or post-chemotherapy
** Low tumour volume, no visceral metastases 
*** no visceral metastases
I: Do you recommend second-line treatment with abiraterone or enzalutamide in
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K: Do you recommend second-line treatment with abiraterone or enzalutamide in
otherwise healthy patients with secondary (acquired) resistance (initial response
followed by progression) to first-line abiraterone or enzalutamide
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Figure 3. Continued
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However, most of the panellists acknowledged that withholding additional
treatment in a patient who knows that his PSA is rising on ADT can be chal-
lenging even without supporting data that any therapy in this stage impacts
overall survival.
The treatment option for such men with M0 CRPC, outside of clinical
trials, chosen by 84% of the panellists was one of the endocrine manipulations
without proven OS benefit (for definition see management of men with non-
metastatic (M0) CRPC section; Figure 3A).
Situation
M0 CRPC
Ca and Vitamin D supplementation
For osteoporosis and increased risk of fractures:
• Bisphosphonate at osteoporosis dose
• Denosumab (60mg, 6-monthly)
A: Do you recommend zoledronic acid (4mg every 3-4 weeks) in castration-naïve M1 patients
with bone metastases?
B: Do you recommend denosumab (120mg every 4 weeks) in castration-naïve M1 patients
with bone metastases?
Ca and Vitamin D supplementation
For osteoporosis and increased risk of fractures:
• Bisphosphonate at osteoporosis dose
• Denosumab (60mg, 6-monthly)
C: Do you recommend an osteoclast-targeted therapy 
for CRPC patients without bone metastases for delaying 
onset of metastases?
Prostate cancer,
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Majority
3%
Majority
3%
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with bone metastases?
E: Do you recommend a dental check for CRPC patients with bone metastases prior to starting an
osteoclast-targeted therapy?
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Figure 4. (A and B) Osteoclast-targeted therapies for men with prostate cancer, March 2015.
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There are no data about the benefits of abiraterone or enzalutamide in
this situation, but three large randomised phase III clinical trials are ongoing
and enrolment of patients with M0 CRPC in such trials is encouraged.
value of endocrine manipulations without proven
survival benefit in men with metastatic CRPC
In the era before the newer AR pathway inhibitors, abiraterone and enzalu-
tamide, were shown to improve overall survival, several drugs were used as
secondary hormonal manipulation in men progressing on ADT. These
drugs are considered as ‘endocrine manipulations without proven OS
benefit’.
The drugs most frequently used are AR antagonists (non-steroidal includ-
ing bicalutamide, flutamide, nilutamide and steroidal cyproterone acetate),
oestrogens and estramustine phosphate, ketoconazole and corticosteroids
(dexamethasone and prednisone/prednisolone). These agents have been
tested in numerous small short-term phase II trials, demonstrating biochem-
ical and/or clinical responses. One phase III trial (n = 260) tested AR antag-
onist withdrawal and ketoconazole plus hydrocortisone compared with AR
antagonist withdrawal alone. The addition of ketoconazole resulted in an im-
provement in the response rate (PSA and objective), but not OS, although
there was considerable crossover [48].
In the absence of large randomised phase III trials, the effect of these
drugs on OS remains unknown. The advantages of the above-mentioned
drugs are their relatively low cost, widespread access and, for some, their
rather favourable safety profile.
For a patient who is not considered a candidate for chemotherapy, 52% of
the panel members felt that in the era of AR pathway inhibitors with proven
overall survival benefit (abiraterone and enzalutamide), these older agents are
not appropriate treatments, if abiraterone and enzalutamide are available.
Nevertheless, 32% would use them in a minority of selected patients and 16%
in the majority of patients.
If abiraterone and enzalutamide are not available, all panel members con-
sidered it appropriate to use these agents (endocrine manipulations without
proven OS benefit), 88% in the majority of patients, the remaining panel
members in a minority of selected patients.
Even in countries where abiraterone and enzalutamide are officially avail-
able, not all patients have access to these agents, either because the ‘out of
pocket cost’ that has to be paid by the patient is too high (e.g. United States)
or because the drugs are not reimbursed in some countries.
The preferred first treatment option among these alternate endocrine
agents was an AR antagonist such as bicalutamide for 63% of the panel
members, while another 25% of panel members would use dexamethasone (of
note, 0% would use prednisone) in this setting. Six percent of the panel recom-
mended ketoconazole in this situation; however, availability of this agent is
limited in many countries.
treatment choice and sequencing for men with
metastatic CRPC
To date, six therapies have been shown to prolong survival in men with
metastatic CRPC. After docetaxel became the first approved therapy to
prolong survival for men with metastatic CRPC in 2004, two registration-
driven (i.e. not based on disease biology) treatment ‘spaces’ for patients with
CRPC evolved, defined by application of chemotherapy: pre-docetaxel
(chemotherapy-naïve) and post-docetaxel. Abiraterone and enzalutamide
have both been investigated and shown to prolong overall survival in large
phase III trials in both the pre- and post-docetaxel states [3, 4, 6, 7].
Sipuleucel-T was tested predominantly (85%) in chemotherapy-naïve men
with CRPC [2]. Cabazitaxel was exclusively tested in patients progressing on
or after docetaxel [1]. The phase III trial with radium-223 included post-doc-
etaxel patients (57%) or patients who were judged as unfit for chemotherapy,
those who declined docetaxel, or had no access to chemotherapy [5]. The
trials of abiraterone and enzalutamide excluded patients treated with the
other novel AR pathway inhibitor, and abiraterone and enzalutamide were
either not available or only available as part of clinical trials when the trials
of docetaxel, sipuleucel-T, radium-223 and cabazitaxel were conducted.
Evidence from a number of small retrospective cohort studies suggests
limited activity from whichever of abiraterone and enzalutamide are used
second in a sequential fashion [49–53]. Docetaxel after one or both of newer
AR pathway inhibitors may have less activity than in the pivotal trials [54–
56]. Cabazitaxel used in the third-line setting post-docetaxel and after one or
two lines of newer AR pathway inhibitors abiraterone or enzalutamide seems
to have similar anti-tumour activity when compared with that seen in the
phase III trial [57–59]. It is of note that all of these studies were not only
retrospective but had small patient numbers and heterogeneous patient
populations and largely represented mono- or oligocenter experiences.
These investigations can be considered hypothesis generating for the devel-
opment of properly powered randomised, prospective trials.
Prospective phase III trial data of novel agents in the second line are only
available in men with CRPC who had been treated with first-line docetaxel.
In daily practice, clinicians often face the difficult task of choosing among
treatment options with different mechanisms of action, administration and
toxicity profiles. Importantly, these agents have not been compared with one
another prospectively. Optimal sequential use of agents with potential for
survival prolongation as well as the optimal time point to initiate treatment
remains uncertain.
Physicians also are challenged by the problem that the average man with
CRPC might not have fulfilled the selection criteria for all of the registration
trials. Also patients enrolled in clinical trials were monitored closely with
bone scintigraphy and CT scans. Therefore, this raises an important question
on whether the trial results may be generalised and extrapolated for a specific
patient.
Sixty-three percent of the panel recommended that in patients with meta-
static CRPC progressing by PSA without evidence of radiographic progression
and in the absence of symptoms and imminent complications, agents with po-
tential for survival prolongation should be initiated within 4–8 weeks.
Conversely, 38% of the panel felt that in such patients treatment can be post-
poned in the presence of adequate disease monitoring.
The most meaningful definition of asymptomatic/mildly symptomatic
(related to pain) men with metastatic CRPC was considered by 71% of the
panel to be ‘No pain medication or only PRN (as needed) pain medication’.
Fatigue and loss of appetite were mentioned as other important symptoms of
the disease.
AR pathway inhibitors. There was consensus (88% of the panel) that
abiraterone or enzalutamide are recommended as first-line therapy for
otherwise healthy, asymptomatic or minimally symptomatic men with CRPC
in addition to ADT (Figure 3B).
Both pivotal trials of abiraterone (COU-302) and enzalutamide (PREVAIL)
in the pre-chemotherapy setting have only included asymptomatic or minimal-
ly symptomatic patients [defined as asymptomatic (score 0–1) or mildly symp-
tomatic (score 2–3) on question 3 of the brief pain inventory short form]
[6, 7]. Prior treatment with ketoconazole was not allowed for both trials.
There was consensus (77% of the panel) that it is appropriate to extrapolate
the results of the COU-302 and PREVAIL trials to certain symptomatic
chemotherapy-naïve men with CRPC; however, 23% did not support this ex-
trapolation. It is important to recognise that symptoms are not the only clinic-
al factor to take into consideration when making a treatment choice (see
section on predictive markers and clinically important factors for decision
making in daily clinical practice).
In contrast to the PREVAIL trial, the COU-302 trial excluded patients
with visceral (lung and liver) metastases.
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There was consensus (88% of the panel) that it was appropriate to extrapo-
late the results of COU-302 to certain chemotherapy-naïve patients with vis-
ceral metastases. This may be based on the fact that abiraterone in the post-
chemotherapy setting had activity in patients with visceral metastases; 12% of
the panel felt that this extrapolation was not appropriate.
With regard to the preferred first-line AR pathway inhibitor, the panel was
almost equally divided between abiraterone (39%), enzalutamide (27%) or
either one of the two (33%).
Since there are no head-to-head trials comparing these two agents, indi-
vidual patient factors such as co-medication (several drug interactions have
been described for both abiraterone and enzalutamide), co-morbidities as
well as patient preference concerning the expected side-effects are important
when making a shared choice for either of the AR pathway inhibitors (e.g.
abiraterone: low potassium, fluid retention, impaired liver function and
cardiac side-effects; enzalutamide: fatigue/asthenia, risk of seizures, QTc pro-
longation).
Based on the available retrospective data that indicate impaired activity of
the AR pathway inhibitors when used sequentially, the panel did not recom-
mend (55%) or recommended only in a minority of selected patients (42%)
second-line treatment with abiraterone or enzalutamide in patients judged to
have primary (innate) resistant disease (no PSA decline, no radiological soft-
tissue response, no clinical benefit) to first-line enzalutamide or abiraterone
(Figure 3C).
In the case of acquired resistance (initial response followed by progression)
to first-line abiraterone or enzalutamide, 24% of the panel did not recom-
mend, and 53% recommended only in a minority of selected patients, the
other AR pathway inhibitor as immediate next-line treatment.
docetaxel. The panel did not (49%), or only in a minority of selected
patients (42%), recommend docetaxel chemotherapy as first-line therapy for
otherwise healthy asymptomatic/minimally symptomatic men with CRPC. In
symptomatic patients, the panel was divided, with 41% recommending
docetaxel as first-line treatment in the majority and 50% in a minority of
selected patients (Figure 3B).
When an otherwise healthy symptomatic patient had a short response
(12 months) to primary ADT, the proportion changed to 56% of the panel
recommending docetaxel in the majority of patients and 41% in a minority of
selected patients. In contrast, in patients with a short response to primary
ADT, but who are asymptomatic or minimally symptomatic, the panel did not
(21%), or only in selected patients (49%), recommend docetaxel as first-line
treatment.
radium-223. The panel did not recommend (33%) or recommended only
in a minority of selected men with CRPC (55%) radium-223 as first-line
treatment.
This may reflect the fact that the chemotherapy-naïve patient population
included in the ALSYMPCA trial was mixed and not well defined: it is not
possible to distinguish the groups of patients who were unfit for chemother-
apy, unwilling to have chemotherapy, or who had no access to chemotherapy
as these data were not collected. Furthermore, activity of radium-223 is
limited to the bone environment and a significant proportion of men with
CRPC have soft-tissue (nodal and/or visceral) disease (Figure 3B) [60].
Combination trials of this agent with other agents with a proven survival
benefit are ongoing. Routine use of combination therapy should not be
undertaken until these data are available.
Sixty-five percent of the panel felt that it was appropriate to extrapolate the
results of the ALSYMPCA study to certain symptomatic men with CRPC with
bone metastases who qualify as fit for chemotherapy. Furthermore, 56% of the
panel felt that it was also appropriate to extrapolate the results of ALSYMPCA
to certain asymptomatic patients with bone metastases, whereas 44% felt that
this extrapolation was not appropriate.
sipuleucel-T. The panel was divided with regards to recommending
sipuleucel-T as first-line therapy for otherwise healthy, asymptomatic men
with CRPC without visceral metastases; 23% recommended it in the majority
of patients, 33% only in a minority of selected patients, and 43% did not
recommend it. This may be due to the fact that experience with the agent is
limited to very few countries (and in fact, relatively few physicians), the fact
that the agent has no detectable direct antitumor activity, and logistics are
challenging. There was consensus (90% of the panel) that it is inappropriate to
extrapolate the results of the IMPACT study to patients who are symptomatic
and/or have visceral disease (Figure 3B).
Sipuleucel-T is currently only available in the United States and market-
ing authorisation in Europe was withdrawn recently.
cabazitaxel. In the second-line setting after first-line docetaxel (before
abiraterone/enzalutamide/radium-223), 9% of the panel recommended
cabazitaxel in a majority of patients, 57% in a minority of selected patients
and 31% did not recommend it.
In third-line after second-line docetaxel (post first-line abiraterone or enza-
lutamide), however, 73% of the panel recommended cabazitaxel in a majority
of patients, while 24% recommended it in a minority of selected patients
(Figure 3C).
staging and monitoring of treatment
baseline staging. Baseline staging and assessment of effects of
anticancer-treatment of patients treated with agents with a proven survival
benefit outside of clinical trials in daily clinical practice remains a challenge
[61], and most current guidelines (e.g. ESMO, NCCN, EAU) do not provide
clear recommendations. The Prostate Cancer Working Group 2 (PCWG2)
recommendations provide clear and detailed instructions on baseline staging
and treatment monitoring, but PCWG2 focused on clinical trials and was
not intended as a guide for routine clinical care [62].
Laboratory and imaging parameters are subject to considerable uncer-
tainty. Disease monitoring in the bone is especially difficult with well-
described bone lesion flare phenomena both on CT and bone scans [63–65].
In addition, there are only well-defined criteria for progression on bone
scans, with no specific criteria for the positive identification of benefit/re-
sponse. PSA alone is not reliable enough for monitoring disease activity in
advanced CRPC, since visceral metastases may develop in men without
rising PSA [60].
PCWG2 recommends a combination of bone scintigraphy and CT scans,
PSA measurements and clinical benefit in men with CRPC [62], while
NCCN includes also MRI and PET, which are reported as ‘useful’
techniques.
Advanced MRI techniques include endorectal MRI, high magnetic field
scanning (3-Tesla), high resolution T2-weighted imaging, contrast
enhanced MRI and diffusion-weighted imaging. Multi-parametric MRI
(T2-weighted imaging together with one or more of the before mentioned
functional techniques) shows great promise for detecting local recurrence
[66, 67]. Advanced spinal/whole-body MRI techniques are also better able
to identify and gauge the extent of bone disease than planar bone scans
[41, 43, 68].
PET/CT can be carried out with different tracers, enabling exploration of
different features of the cancer and its interactions with bone. At present,
choline PET/CT (either labelled with 11Carbon or 18Fluoride) is the ap-
proach for which there is most information, with data suggesting good ac-
curacy for detection of recurrence [69], but validation with randomised
prospective trials is still lacking. Also, solid data on new promising tracers
(such as PSMA) are still lacking.
There was clear consensus with the panel recommending unanimously
(100%) that imaging should be undertaken in men with metastatic CRPC
before starting a new line of treatment.
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Baseline examinations should include history and clinical examinations as
well as baseline blood tests such as blood count (haemoglobin, thrombo-
cytes, total white blood cell count, neutrophil and lymphocyte counts), alka-
line phosphatase (ALP) and lactate dehydrogenase (LDH). Some of these
variables (Hb, LDH, ALP) are considered established prognostic factors;
however, their value in directing treatment decisions is not established. In
addition, other assessments such as renal and liver function as well as elec-
trolytes should be carried out.
There was clear consensus that a CT scan of the chest thorax and
abdomen-pelvis (91% of the panel) and bone scintigraphy (83% of the panel)
should be recommended in the majority of patients before starting a new treat-
ment.
It is recognised that planar bone scintigraphy has short-comings and is
less sensitive than other newer imaging technologies (e.g. MRI of the axial
skeleton for bone staging, MRI of the whole body and/or PET/CT for con-
current bone and node metastasis screening). But availability of these
newer imaging technologies is limited and their added value over bone
scintigraphy in the management of APC, i.e. impact of earlier and more re-
liable detection of metastasis on complications and survival, has not been
proven.
Malignant spinal cord compression (MSCC) occurs at a frequency of 4%–
8% in men with CRPC and is one of the most devastating complications [5].
The panel stressed the need for a risk-adapted approach to undertaking MRI
of the entire spine. Retrospective, small studies have shown occult spinal
cord compression or impingement in up to 30% of men with CRPC [70, 71].
Extensive bone metastatic disease on bone scan was shown in both studies to
be an independent predictive factor for MSCC. A large randomised phase III
clinical trial comparing screening MRI of the spine to standard of care is
ongoing (CRUK/11/053).
Seventeen percent of the panel recommended a baseline MRI of the entire
spine in the majority of patients and 54% in a minority of selected patients
based on extent of spinal metastases on bone scintigraphy or CT scan.
In case of neurologic symptoms possibly indicating MSCC, a MRI of the
whole spine should be done immediately.
In routine practice, the panel did not (47%) or only in a minority of selected
patients (36%) recommend the use of newer imaging methods beyond bone
scintigraphy and CT scan, namely whole-body MRI and/or PET/CT, as a
components of baseline prostate cancer staging.
The variability in cost and availability of newer imaging modalities
throughout the world, and lack of definitive data concerning their prognostic
and/or predictive value makes this area an important unmet medical need
for research.
treatment monitoring. There was consensus (83% of the panel) that
regular monitoring of treatment (apart from clinical and laboratory
assessment) is recommended for men with metastatic CRPC. This reflects the
fact that the agents with a proven overall survival benefit all have potential
toxicity and considerable costs, and patients with no objective benefit
(including disease stabilisation) should not be further exposed to them. It was
discussed that, for imaging, generally a risk-adapted approach should be
considered depending on response to therapy, extent of disease and clinical
situation (e.g. line of therapy, symptoms).
The panel recommended regular measurements of ALP (88%) and LDH
(61%). Both markers may be helpful as serial values when it comes to inter-
pretation of discordant results (e.g. PSA rise and clinical improvement).
The panel stressed the need for cautious interpretation of PSA values es-
pecially in the first 2–3 months after starting a new treatment. PSA flare has
been described following initiation of chemotherapy or newer hormonal
therapies with significant PSA falls after initial rise [72–74].
For sipuleucel-T and radium-223 no significant PSA declines have been
reported despite an OS benefit. Education of patients and physicians about
uncertainties in interpretation of PSA values is critical.
Eighty-three percent of the panellists did not recommend regular monitor-
ing or monitoring at progression with MRI of the entire spine in patients with
multiple spine lesions on bone scintigraphy but rather stressed the need for
a risk-adapted approach largely dependent on the development of clinical
symptoms.
Further studies are necessary to confirm the potential role of systematic
disease monitoring using MRI or PET/CT to characterise early response
to treatment (i.e. recognition of disease response, stability or progression
and not only late confirmation of progression) and its potential impact
on the sequential use of agents with a proven overall survival benefits
[68, 75–78].
monitoring of men treated with abiraterone or enzalutamide.
With regard to PSA measurements 62% of the panel recommended a
frequency of every 2–4 months, and 38% recommended measurement every 3–
4 weeks. There was consensus (78% of the panel) that regular CT scans even
in the absence of clinical indication (e.g. new symptoms or pain) should be
carried out. With regards to frequency, 47% of the panel would perform CT
scans every 2–4 months and 31% every 6 months. Nineteen percent of the
panel recommended CT scans only if clinically indicated.
The panel also recommended regular bone scintigraphy. With regards to
frequency 27% of the panel would perform bone scans every 2–4 months and
59% every 6 months.
monitoring of men treated with docetaxel or cabazitaxel. There
was consensus (79% of the panel) that PSA measurement should be undertaken
every 3–4 weeks while 21% of the panel recommended measurements every 2–4
months. There was consensus (80% of the panel) that regular CT scans even in
the absence of clinical indication (e.g. new symptoms or pain) should be carried
out. With regard to frequency, 66% of the panel would perform CT scans every
2–4 months and 14% every 6 months Seventeen percent of the panel
recommended CT scans only if clinically indicated.
The panel also recommended regular bone scintigraphy. With regard to
frequency, 36% of the panel would perform bone scans every 2–4 months and
33% every 6 months. Twenty-four percent of the panel recommended monitor-
ing bone scintigraphy only if clinically indicated.
monitoring of men treated with radium-223 or sipuleucel-T. The
panel was split about the recommendation for PSA measurement and
recommended every 3–4 weeks (44%), every 2–4 months (34%), or only if
clinically indicated (19%). The panel recommended regular CT scans with a
frequency of every 2–4 months (42%) or every 6 months (21%). Thirty percent
of the panel recommended CT scans only if clinically indicated.
For sipuleucel-T no significant imaging response rates have been shown
in the phase III trial, and for radium-223 no imaging was carried out in the
phase III trial. Monitoring may therefore primarily be helpful to exclude sig-
nificant disease progression. For radium-223, the value and interpretation of
imaging for monitoring are unclear and should therefore be addressed in
clinical trials.
indication to stop treatment. The panel stressed the fact that
treatments with a proven survival benefit should in general not be stopped for
PSA progression alone (in the absence of radiographic or clinical progression).
There was consensus (82% of the panel) that at least two of three criteria (PSA
progression, radiographic progression and clinical deterioration) should be
fulfilled to stop treatment. In the case of unequivocal progression of visceral
disease without clinical deterioration or PSA progression, treatment should be
stopped and a biopsy can be considered to rule out secondary malignancy or
small-cell histology. In case of significant clinical progression that is very likely
related to disease without a rise in PSA or radiographic progression, treatment
should be changed. It should be recognised that men with CRPC can often
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have worsening bone pain related to non-malignant processes such as
degenerative disorders or osteoporotic fractures. Similarly, fatigue/asthenia
can be a side-effect of treatment and may therefore not be a sign of disease
progression.
use of osteoclast-targeted agents for reducing risk
of SREs and SSEs in men with CRPC
In men with CRPC and bone metastases, two agents (zoledronic acid and
denosumab) have been approved for reducing risk of SREs defined as: radi-
ation to the bone, surgery to the bone, fractures, spinal cord compression
and (for zoledronic acid only) change in antineoplastic therapy. In the
pivotal trial by Saad et al., zoledronic acid was given at a dose of 4 mg every
3 weeks for a total of 20 cycles (15 months) with an option to continue for
an additional 9 months extension (24 months) [9, 10]. It is of note that the
trial included a third arm using 8 mg every 3 weeks, which was reduced sub-
sequently to 4 mg because of renal toxicity, and this arm did not show sig-
nificant reduction of SREs compared with controls.
The dose of denosumab in the pivotal trial by Fizazi et al. was 120 mg s.c.
every 4 weeks until discontinuation or until the primary cut-off date, which
occurred about 41 months after start of enrolment [79]. Both zoledronic
acid and denosumab were developed and investigated before the era of
agents with significant anti-tumour effect and survival impact for men with
CRPC. For abiraterone post-docetaxel, or enzalutamide both pre- and post-
docetaxel, a significant reduction in the time to first SRE in the active treat-
ment arms was reported [7, 80, 81].
For radium-223, also a bone targeting agent, there was also a significant
prolongation in time to first SSE in the overall trial population and also in
the subgroup of patients receiving bisphosphonates [82].
The optimal timing for starting treatment, optimal treatment intensity
(dose and frequency) and optimal duration of osteoclast-targeted agents for
men with CRPC is unclear. Also treatment-related toxicity (e.g. osteonecrosis,
hypocalcaemia and hypophosphataemia) has to be taken into consideration.
Overall, 62% of the panel recommended that the majority of men with
CRPC with bone metastases should receive an osteoclast-targeted agent for
prevention of SRE. Thirty-two percent of the panel recommended osteoclast-
targeted treatment in a minority of selected patients. If these treatments are
planned there was consensus (76% of the panel) that a professional dental
check (dentist) should be undertaken at baseline before treatment start in the
majority of patients (Figure 4B).
The panel was almost equally divided as to preference between zoledronic
acid (30%), denosumab (42%) and either of the two options (27%). This
voting result may be influenced by the fact that zoledronic acid has become
generic influencing the cost of the treatment.
Regarding the frequency of treatment administration for zoledronic acid or
denosumab, 31% of the panel recommended dosing every 3–4 weeks, 34%
recommended less frequent administration from the beginning and 28%
recommended a 3–4 weekly dosing for2 years and less frequently after that.
This is distinct from the regulatory approvals and likely represents the
lack of data supporting a dose response for these agents.
Half of the panel was of the opinion that osteoclast-targeted therapy should
be continued indefinitely, whereas 47% of the panel recommended a total dur-
ation of2 years for reducing risk of SREs/SSEs.
For men with metastatic CRPC and bone metastases responding to a treat-
ment, 58% of the panel were of the opinion that osteoclast-targeted therapy
should be continued at the same schedule, whereas 26% voted for decreased
frequency and 16% recommended interruption or discontinuation of the
osteoclast-targeted therapy.
Denosumab has been compared with placebo in men with CRPC without
bone metastases. Its use led to increased bone metastases-free survival but
no overall survival benefit in a large phase III clinical trial [8]. No country
has approved denosumab for men without bone metastases.
For men with CRPC without bone metastases, there was consensus (88% of
the panel) that an osteoclast-targeted agent for delaying onset of bone metas-
tases is not recommended (Figure 4A).
predictive markers and clinically important factors
for decision making in daily clinical practice
The panel stressed the need for predictive markers indicating sensitivity or
resistance to a specific therapy.
There was clear consensus (94% of the panel) that, at present, there is no
validated and established marker that can be used as a predictive factor in
daily clinical practice to inform on treatment choices for men with CRPC.
Factors favouring chemotherapy instead of AR pathway inhibitors with a
proven overall survival benefit were discussed. The panel was of the opinion
that a Gleason score of 8 (88% no) and a circulating tumour cell count of
5/7.5 ml (97% no) as single factors should not influence this decision. Also,
in patients with extensive disease on imaging, 68% of the panel was of the
opinion that this factor alone should not influence treatment choice for men
with CRPC.
For several other factors, the panel was divided as to whether these factors
would favour use of chemotherapy instead of abiraterone or enzalutamide: ex-
pression of AR-V7 splice variants (47% yes, 44% no), presence of visceral me-
tastases (50% yes, 50% no), short response (12 months) to primary ADT
(53% yes, 47% no) and low PSA (<20 ng/ml) in the setting of high tumour
volume (65% yes, 35% no).
In daily clinical practice, decision making is based on many patient-,
tumour- and environment-related factors as well as patient and physician
preference and the cost and availability of drugs.
tumour biopsy
Fresh tumour biopsies in men with CRPC are increasingly incorporated into
clinical trials and advances in imaging and in laboratory technology have
made the processing of biopsies from bone metastases feasible [83–87].
It is unclear when a biopsy from a man with CRPC should be considered.
Tumour biopsies should only be carried out, if the procedure can be
done without unreasonable risks, if adequate handling and analysis of the
tissue is ensured, and if the result has potential implications for patient man-
agement. In a subset of men with CRPC, an AR signalling-independent
phenotype may develop which can be associated with small-cell carcinoma
seen on biopsy and clinically with rapidly progressing visceral metastases,
predominately lytic bone metastatic disease and stable or low PSA levels.
Recommendations from a multidisciplinary committee on aggressive var-
iants of CRPC have been published recently [88]. The optimal treatment in
these patients is unclear but platinum-based therapy is often recommended
for patients with small-cell carcinoma and sometimes for patients with
aggressive clinical features. There are limited data regarding the management
of men with CRPC with neuroendocrine differentiation or other atypical
morphology.
The panel discussed a number of clinical factors that may indicate that a
tumour biopsy should be considered, low PSA (<20 ng/ml) in the setting of
high tumour volume (44% yes in the majority, 47% yes in a minority, 9% no);
new development of visceral metastases (32% yes in the majority, 56% yes in a
minority, 12% no); progressive lesions in case of discordant tumour response
to treatment (49% yes in the majority, 46% yes in a minority, 6% no); predom-
inately lytic bone metastatic disease (37% yes in the majority, 37% yes in a mi-
nority, 26% no); patients progressing on primary ADT within <6 months
(23% yes in the majority, 31% yes in a minority, 46% no).
multidisciplinary care of men with prostate cancer
Multidisciplinary care of men with APC has become much more complex in
recent years. The involvement of physicians with expertise in distinct
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domains of cancer care is crucial in order to achieve the best possible care
for men with APC.
Half of the panel members recommended that patients should be discussed
in a multidisciplinary team (MDT) before a new line of therapy is started and
44% recommended discussion by the MDT in a minority of selected patients.
Although the importance of MDTs is acknowledged, time constraints are the
main reason for not discussing all but only complex patient cases in a MDT.
There are also clear differences between different health systems, since in some
countries discussion in a MDT is a prerequisite for insurance companies to
cover the costs of the treatments.
There was strong consensus (94% of the panel) that patients should be
informed about the possibility of participating in a clinical trial to improve
knowledge of the disease.
Also 64% of the panellists recommended early access of men with CRPC to
an expert in symptom palliation or a dedicated palliative care service.
discussion
In the absence of level one evidence or in areas where there are
conflicting data or conflicting interpretation of existing data,
weighted expert recommendations are helpful for making treat-
ment decisions in daily clinical practice. That was the motiv-
ation and goal to initiate the APCCC where prostate cancer
experts discussed and voted for different management options
for men with APC.
In some areas, there was clear consensus (supplementary
Appendix S2–S4, available at Annals of Oncology online) among
the prostate cancer experts whereas, in other areas of approaches
to patient care, there were divergent opinions. Some of the vari-
ation may be due to different patient management philosophies
in different geographic regions; other differences may result
from lack of data.
Areas of consensus included the definition of castration resist-
ance where there was consensus that rising PSA with a docu-
mented testosterone level <50 ng/dl (<1.7 nmol/l) on ADT
alone is sufficient and no secondary hormonal manipulations
are required. There was also consensus that, in men with meta-
static CRPC, staging examinations, including imaging, have to
be carried out before each new line of treatment. Regular treat-
ment monitoring with imaging was also recommended for men
with CRPC. There was strong consensus that currently there is
no validated predictive factor for treatment selection available. In
men with castration-naïve prostate cancer, the use of osteoclast-
targeted therapy with denosumab or zoledronic acid for reducing
risk of SREs or SSEs was not recommended. The same is true for
men with CRPC without bone metastases. There was consensus
that treatment of CRPC should generally only be stopped if two
of three criteria (PSA-, radiographic or clinical progression) are
fulfilled. There was strong consensus that patients should be
informed about the possibility of joining a clinical trial.
The topics which generated disagreement among the panel
should serve as potential areas for research and should be
addressed in future clinical trials. Such areas include chemo-hor-
monal therapy in castration-naïve disease, but lack of consensus
may be resolved by the results of the STAMPEDE trial. Another
area of discrepant opinions is the treatment of M0 CRPC disease
and three large phase III trials in this setting are ongoing.
In the first-line setting for men with CRPC, there seems to be
considerable uncertainty. There was no consensus as to whether
abiraterone or enzalutamide should be chosen, if the option of a
newer AR pathway inhibitor is considered. Also the role of
radium-223 in this setting seems controversial. There was not a
single factor that the panel recommended to use for choosing
chemotherapy first line. Biomarkers capable of informing specific
applications and sequencing of treatments are of special interest
for future research. Another open question is sequencing of ther-
apies and specifically the use of abiraterone or enzalutamide after
progression on the other one of them after initial response.
An important unmet medical need is the assessment of value
of the newer imaging modalities in early diagnosis and treat-
ment monitoring and their impact on patient outcome. The
variability of cost and availability of these imaging modalities
throughout the world are also an issue. Prospective multicentric
translational studies embedding these newer modalities are
needed to confirm the ability of these techniques to do better than
bone scintigraphy and CT in terms of disease detection, demon-
stration of recurrence and to provide an earlier, more refined ap-
proach of response evaluation and defining the optimal timing to
switch treatment or type of treatment. Importantly, they need to
be assessed in terms of their impact on QoL measures and sur-
vival, although the latter is likely to be more challenging given the
availability of multiple survival-prolonging treatments.
Furthermore, new ‘registration’ end points are needed in the
light of several drugs that have been shown to prolong median OS.
Another area of uncertainty is the ‘best use’ of osteoclast-
targeted agents in men with CRPC concerning initiation, dose,
frequency and duration. It is also unclear if, in the time of
potent new therapies, the effect of these agents is redundant or
additive, and that may depend on the new therapy used. The
management of men with oligometastatic disease is another area
where trial data are lacking and no consensus could be achieved,
which makes it an important research question. More data are ne-
cessary to address the above topics where consensus is lacking,
and this conference pointed to clinical issues where physicians
make decisions without certainty of benefit. If the gaps in knowl-
edge are not filled with informative rigorous data, future regula-
tors and payers may decide how a patient will be treated.
We did not capture differences in the opinion of panel
members by geographic region, access to drugs or imaging or by
different patient ethnic groups or cultures. This will be consid-
ered at the next meeting.
Additional important questions remain that have not been
addressed in this meeting such as costs and cost-effectiveness of
drugs, drug accessibility, ideal clinical settings, health economic
issues, patient-reported QoL outcomes, implementation of pre-
cision medicine strategies in clinical practice as well as combin-
ation strategies.
The panel predicts that by the next APCCC in 2017 some of
the unanswered questions will be better understood or hopefully
clarified by emerging data. Additional questions will then be
addressed to provide further recommendations useful for daily
clinical practice: in particular selecting the right treatment, for
the right patient and at the right time.
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Background: Pulmonary carcinoids (PCs) are rare tumors. As there is a paucity of randomized studies, this expert con-
sensus document represents an initiative by the European Neuroendocrine Tumor Society to provide guidance on their
management.
†See the ENETS consensus group members in the Appendix section.
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